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Rapid and accurate assessment of allograft function 
in the early postoperative period is critical for successful 
liver transplantation. This study evaluated the efficacy 
of lecithin:cholesterol acyItransferase (LCAT) activity 
as an indicator of early allograft function in human 
orthotopic liver transplantation (OL Tx), During a three-
month period between September and No\'ember 1987, 
9 of 11 adult OLTx recipients whose graft exhibited 
poor function were studied. Poor graft function was 
defined as primary nonfunction, need for retransplan-
tation within a week after OL Tx, or elevation of the 
prothrombin time o\,er 20 sec early after OLTx. Plasma 
LCAT acti\'ities (measured pretransplant and at 0, 6, 
12,18, and 24 hr, as well as 3 days, after OLTx) and' 
pretransplant clinical variables were compared with 
those of 15 control patients whose graft exhibited good 
function. A significant correlation was found between 
mean LCAT activities during the first 24-hr after OLTx 
and early allograft function (P<O.05, x2=5.23), When 
pretransplant histological findings of the 6 grafts with 
poor function and the 15 controls together were corre-
lated with the mean LCAT activity within 24 hr follow-
ing OL Tx, a significant association was demonstrated 
(P<O,05). This study suggests that plasma LCAT activ-
ity is an effective and practical method for assessing 
early allograft function following OLTx. 
Since the first human orthotopic liver transplant (OLTx) 
performed in 1963, enormous progress has been made in the 
overall management and survival of patients with end-stage 
liver diseases (J-3), Factors responsible for this improved out-
come include the introduction of cyclosporine (4), the use of 
venovenous bypass (5), and a standardizatie,n of the technique 
of biliary tract reconstruction (6). The recent introduction of 
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University of Wisconsin (UW) solution by Belzer et al. (7, S) 
for preservation of the liver has improved the results e\'Cn 
further, and has allowed the procedure to be performed more 
widely. However, graft nonfunction either primary, or second-
ary due to technical failure--remains a major complication of 
OLTx, and one that carries a high morbidity, mortality, and 
need for retransplantation (9). In an earlier studies (JO), we 
have demonst rated that the most commonly used donor char-
acteristics did not distinguish between grafts that functioned 
and those t hat failed to function. Moreover, only a few studies 
have been reported on allograft viability in the early postoper-
ative period \11-16). 
Lecithin:cholesterol acyltransferase (LCAT), an enzyme that 
esterifies free cholesterol (J 7) and functions in the transporta-
tion of cholesterol and the metabolism oflipoproteins (IS), has 
been known to be useful in assessing liver function following 
hepatic resection or other surgical procedures such as opera-
tions for esophageal varices (J 9), LCAT activity also has been 
shown to be a valuable indicator of prognosis in fulminant liver 
failure (20), Reduced LCAT activity in patients with liver 
diseases is considered to be due to impaired protein synthesis 
occurring secondary to hepatic dysfunction. Based upon the 
data obtained in various types of hepatic diseases, the present 
study was performed to determine if serial quantitati"n of the 
plasma LCAT activity could be utilized as a predictur of allo-
graft function early after OL Tx. 
~iy TERIALS A~a ~1bqelap 
During a three·month period between September 1 and ~ovemher 
30, 1987, 76 OL Tx were performed in 68 adult patients at the Presby· 
terian University Hospital, University of Pittsburgh. The first 42 grafts 
were preserved in Euro-Collins' solution (4"C), while the other 34 were 
stored in University of Wisconsin (L:W) solution (4"Cl. Eleven of these 
grafts (14.5"<) exhibited poor function, as manifested by death due to 
primary non function (two grafts), need for retransplantation within 
the first week after OL Tx (4 grafts), and poor synthetic function with 
a peak prothrombin time of over 20 sec (control 11.8 sec) during the 
first 5 posttransplant days (5 grafts). 
From the recipients of 9 of the 11 grafts with poor function, blood 
samples were obtained at predetermined time points: immediately prior 
to OLTx, immediately after OL Tx; at 6, 12, 18, and 24 hr after OL Tx; 
and at 3 days posttransplant. Plasma was separated from the blood by 
centrifugation at 2000 RPM for 5 min at 37'C and stored at -60"C. 
The selection was random and was based primarily on the availability 
of pretransplant blood samples. Plasma LCAT activity and pretrans-
plant clinical variables of these recipients were compared with those of 
15 recipients with adequate immediate posttransplant allograft func-
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t 1) '1S llnnif(·,t('d by a Iwak SCOT. SePT. and pruthrombin '011 (COil rO I~K-I . • . 
tl f less than :W(JO lL'/L. :zooo IL'/L, and 20 sec, resp<'ctl\ely. 
tIl Ile 0 'Iecithin'chcde,tcrol ac\l\ransferase activity was d('terll1irwd I'h,mn .. . 
. ' 1 CAT test kit,S uiJt:1im·d ff(@ ~ippon Shoji Co" Ltd., O,;:lka, 
-Ing a 0 d Ak 
u, .' g a modification of the method of :-":agasaki an allUllla Japan u"ln .,. . , "d .'d" 
. ) The lllodlficiltle,n '{(IlSI>ts of the adlhtlOn of ascorbIC al'l OXI ase 
(IJ ' • , • 't ~ b 
- d 'c'diulll azide (:\a:\,) tu the mixture to mInimIze In er tf('nee y 
all ' . d I h f 
.' a levels of ascorbic acid and hemoglobm, an a so t e use 0 
pl,,,m I] 3 5 d' th o\OS' (Sodium iD:IethylI~ l~IhFelroxy-:l-sulfoprcDpy -, - 1111E' ox· 
D. '1' e) in~tead of phenol fur the color r('action such that absorb'1l1ce \an J In - f 
: ,d at 600 nm, thereb\' Jlre\enting the influence of the presence 0 IS re,l . ., b'l' 
'I' b'n Plasma LCAT activity was determmed by Its a I Jty to bl IfU I. ,. . . d 
esterify cholesterol at 37'C. A unit of LCAT actIvIty was expresse as 
the reduction in free cholesterol (I'g/ml/hr) In the assay mIxture ... 
In order to assess the associat ion bet ween plasma LC AT aEDtlyD~ty 
and the quality of the allograft, histological findings of the grafts With 
oor fun('tion and thl' controls togHher w~re correlated WIth the LCAT 
p '··tl'es AIl,wraft biopsy was obtained bv a Trucut biopsy needle acll\!" 0 • " ., 
I Travenol Laboratories) immediately pnor to Jmplantatlon Jl1 6 ~f the 
II grafts with poor funrtion and all 15 EDontro~ livers. The biOpsy 
,;pecimens wrrl' fixed with 10'( buffr-red formalm and stilllled WIth 
hematox) lin alld eosin. The hiotological findings WHe graded as follows: 
Grade I (12 grafts)-minirnal or no ('vidence of preservatIOn damage; 
Grade II (9 grafts)--( han"es ('onsj,tE-nt with ischemic injury, a~ man-
ifcsted by diffuse hC]>;ltocellular " .. elling, steatosis, or aCIdophIlIC ne· 
crosis. 
For statistical analysis, the \lann-Whitnl')' e and chi-square tests 
were used. Results of the pL1<ma LeAT activity were expressed as 
means ± SD, 
RESl'LTS 
Table 1 demonstrates the relationship between LCAT activ-
ity during the tirst 24 hr after OLTx and graft function. A 
mean LCAT activity of less than 5 U correlated with poor graft 
function (P<0.05, x'=5.2:3). Table 2 lists the pre· and intra-
operative clinical variables of the patients in each group. No 
significant difference was identified among the clinical paramo 
eters between the two groups. Similarly, preengraftment LCAT 
activity for both groups \\a:; not different. Table 3 lists the 
clinical data of the 9 patients who exhibited poor graft function. 
Three of these 9 patients (cases 6,7, and 8) required retrans-
plantation and one (case 1) died within a week. 
Figure 1 and Table 4 depict the short·term changes of the 
LCAT activity after OLTx. Serial LCAT activity in the group 
with poor liver function was significantly lower than that of 
the group with adequate liver function at 6, 12, and 18 hr and 
at 3 days following OLTx (P< [at most) 0.05). 
Hist;logically, 12 grafts with pretransplant histology grade I 
had a mean LCAT activity within 24 hr after OL Tx of 8.5±4.4 
U, which was significantly higher than 4.6±1.9 U of 9 grafts 
with histology grade II (P<0.05). 
DlSCl:SSIO::vJ 
This study demonstrated a statistically signiticant correla-
tion between early allograft funct ion and the plasma LCAT 
activity in OL Tx recipients during the early postoperative 
period. 
Numerous previous attempts have been made to assess the 
viability of the hepatic allograft prior to and immediately after 
transplantation. Fath et al. (J 1) reported a correlation between 
the ability of the hepatic allograft to reduce abnormal levels of 
• Abbreviations: DADS, sodium N·ethyl-N (2-hydroxy·3·sulfopro-
py!)·3,5-dimethoxyaniline; LCAT, leEDithin:chol~sterolKacyltransferase; 
RPM, rounds per minute; CW, Vniversity of WISCOnSll1. 
TARLE 1. Correlation b~twEen allograft function and mean plasma 
LCAT activity eluring the first 24 hours following OL Tx 
\le"n ["CAT' 
aC("ely IU) 
Al10graft fu net ion 
3 (20.0<;0) 
12 (80.0%) 
Poor 
6 (G6'iCC) 
3 E;P:P:P~F 
~~------I-----
" LCAT, lecithin:cholesterol acyltransferase; OLTx, orthotopic liver 
transplantation. 
b P<0.05 (x '=.,.23). 
TABLE 2. Relationship betwE'en pre· or intraoperati\'e clinical 
variables and early allograft function 
Variables 
Preoperative: 
Age (years) 
Sex (M:F) 
1'. bil (mg,ldl)" 
PT (sec) 
Albumin (g/d!) 
lCG (20') (<;0) 
LeAT (V) 
lntraoperative: 
Blood loss (V) 
Allograft function 
422±12.2 
6:4 
'i.1±8.3 
15.S±2.7 
2.8±O.6 
3/.7±19.6 
6.6±5.6 
12.6±7.9 
Poor 
43.l±li.8 
2:4 
12.7± 1:3.2 
J6.0±3.5 
2.6±0.7 
28.,5-+:24.0 
4.1 ±3.9 
O4K9:+:OK:KU_KM~~_ 
"T, bil, total bilirubin; PT, prot hrombin time; leG 120' J. indocy-
anine green dye retention test at 20 min (normal less than R~ I; LCAT, 
ll'cith in:cholesterol aey It ransfe rase, 
total plasma amino acids immediately following revasculariza-
tion and subsequent postoperative morbidity, defined as reop-
eration, death, or hepatic necrosis during the first 48 hr after 
OL Tx .. Jenkins et al. (] 2) demonstrated that a delayed recovery 
of t he rate of central plasma clearance of amino acids following 
Ii\'er transplantation identifies recipients with an increased 
mortalitv, Taki et al. (13) reported in pigs that a failure to 
maintai~ a normal ratio of ketone bodies after OL Tx correlated 
with hepatic energy charge and predicted a high mortality. 
Kamiike et al. (]4) recently suggested that in humans the 
recovery of ATP levels in liver may be an indicator of early 
allograft function. Mora et aJ. (15) have demonstrated that the 
clearance of serum total bile acids can also serve as a putative 
marker of early allograft function (15). Persson et al. (16) have 
suggested that total-body oxygen consumption, which rapidly 
declines during the anhepatic phase of the transplant procedure 
and returns quickly to baseline levels immediately after revas-
cularization of the graft, may also be a good indicator of early 
graft function and perfusion. All of these methods. however,' 
are sophisticated, cumbersome, or invasive, or they require 
special equipment and expertise, and so cannot be used rou-
tinely and more widely. 
Currently, measurement of the prothrombin time and deter-
mination of the levels of specific coagulation factors remain 
the most practical methods for the assessment of early allograft 
function after OLTx. Clinical features of malfunction of the 
liver allograft after OL Tx include inability to awaken from 
anesthesia, low bile output or production of thin bile through a 
T tube, elevated transaminases and prothrombin time, and 
persistent or progressive hyperbilirubinemia. often followed by 
a rapid development of renal failure and other metabolic de-
rangements. Nevertheless, as exhibited in Table 3, considerable 
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TABLE 3. Clinical data of pHtil'nts ..... ith poor graft function after OLTx 
Peak values within S days after 
OLTx 
~---D-
Cas€' Age (yr)/ Sex Indication fl,r OLTx 
--------~I ---~------~~- Outcome 
sGOT "GPT PT 
(IU/L) (lli/Ll (,ec) 
~-~------~--
1. 70/1" PGl\'F, status after OLTx 4010 4825 24.2 Died of ~llc (3)" 
for PBC 
2. 2:1/F PBC 2677 2902 23.1 ReTx for rejection (60), Doing well 
3. :ll/F P;-';C (NA1\'B) 1818 1260 23.9 Doing well 
4. 61/M Recurrent HB, status 6362 3603 31.6 Died of &epsis (18) 
after OLTx 
5. 44/F P;-';C (alcoholic) 2840 1660 24.0 Prolonged respiratory failurl', CMV 
hepatitis, discharged (234), ooing 
well 
6. 55/F PBC 3035 2135 20.2 ReTx for CMV hl'patitis (31), died 
of sepsis (92) 
7. 211M Cyst ic flbrosis 400 413 22.7 ReTx for HAT (1), died ofpneu-
monia (15) 
8. 29/F PGl\'F, status after OLTx 2805 1820 34.2 ReTx for HAT (3), died of I\WF 
for BC (11) 
9. &4/F Pl\'C (NA!\B) 13,874 5106 46.0 ReTx for PGNF (5), doing well 
-~~-~-~---
'l\'umher of postoptrati,e days; OLTx, orthotopic liver transplantation; PT, prothrombin time; PGl\'F, primary graft nonfunction; MOF, 
multiple organ failure; PBC. primary biliary cirrhosis; ReTx. retransplantation; PNC, post necrotic cirrhosis; 1\'ANB: non-A-non-B hepatitis; 
HB, hepat itis B; CMY, cytomegalovirus; HAT, hepatic artery thrombosis; BC, Buod-Chiari syndrome. 
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FIGl'RE 1. Plasma LCAT activity immediately following orthotopic 
liver transplantation. (0): adequate function group; (e): poor function 
group. (LCAT) lecithin:cholesterol acyltransferase. (U) }Jg/ml/hr at 
37·C. 
TABLE 4. Plasma LCA T activity in adequate and poor function 
groups after OLTx (mean ± SD) 
Plasma LACT activity (U) in each posttransplant hour 
AI10grafl function 
o 6 12 18 24 72 
Adequate En~1RF i.9±S.O 8.7±S.5' 9.8±6.2' 7.2±4.5' 7.1±5.0 11.9±4..8' 
Poor En~9F 4.5±3.0 3.9±3.S' 4.4±3.0· 2.2±2.5' 3.6±4.2 3.5±3.4' 
• P<O.05. 
, P<O.OI. 
variations exist in the clinical presentations of liver failure 
immediately after OL Tx. 
The prothrombin time is a practical and simple laboratory 
study that indirectly reflects the production of coagulation 
factors by the hepatic allograft. Transaminases, on the other 
hand, are indicators of hepatocellular breakdown rather than 
of allograft function that generally take several days to peak. 
When the elevation of the prothrombin time (over 20 sec in 
adults and 30 sec in children) is identified immediately after 
OL Tx, we administer fresh frozen plasma to avoid complica-
tions related to coagulopathy, such as intracranial or intraab-
dominal hemorrhage. Introduction of extrinsic coagulation fac-
tors, however, may complicate the interpretation of t he pro-
thrombin time as an indicator of allograft function. 
Plasma LCAT activity, on the other hand, has been well 
accepted in Japan as an indicator of liver failure following 
hepatic resection or other surgical procedures for liver disease. 
LCAT is synthesized in the liver (22,23), has a function half-
life of 5-6 hr (24), and is not thought to be affected by the 
administration of fresh frozen plasma. Moreover, it can be 
measured within about 2 hr without any requirement for unique 
expertise or equipment. We therefore believe that it may be 
more useful than current methods-i.e., prothrombin timl' and 
coagulation factor levels-for evaluating early hepatic allograft 
function. 
The relationship between the preimplantation histology of 
the liver allografts and the plasma LCAT activity in the recip-
ient immediately following OL Tx suggests that LCAT activity 
at this time may reflect the condition of the donor liver prior 
to organ procurement and the dl'gree of preservation or reper-
fusion injury inflicted upon the allograft. 
In summary, plasma LCAT activity assayed immediately 
following OL Tx is a simple, reliable, and inexpensive parameter 
that may provide a rapid estimation of allograft function and 
prediction of outcome following OL Tx. 
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COAGULATION CHANGES FOLLOWING HEPATIC 
REV ASCULARIZATION DURING LIVER TRANSPLANTATION! 
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The coagulation changes during liver transplantation 
have becn studied in 14 selected patients. Blood usage 
in all cases was limited to 8.5 liters, and the preoperative 
coagulation results were only minimally deranged. 
Bleeding during the operative procedure was easily 
'This work was supported by the British Heart Foundation 
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matology. University of Cambridge, Addenbrooke's Hospital, Cam-
bridge, C'B2 2QQ, l'nited Kingdom. 
1 Department of Haematology. 
• Df'partmenl of Anaesthetics. 
'Department of Surgery. 
managed in all cases. Nonetheless, even in this selected 
group of "low risk" patients, we have demonstrated that 
during the anhepatic phase and particularly following 
hepatic revascularization there is activation of both co-
agulation and fibrinolysis. These findings imply that if 
bleeding occurs following revascularization, in addition 
to the use of replacement blood products, treatment 
should be directed at reducing the consumptive coagulop-
athy and inhibiting fibrinolysis. We suggest as a first 
step antithrombin supplementation to maintain activity 
above 70%, and an antifibrinolytic agent, such as apro-
ton in, should be considered as adjuncts to therapy at 
revascularization. 
